Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
29 results
  • Pancreatic Cancer, Ovarian Cancer, Liver Cancer, Gastric (Stomach) Cancer, Breast Cancer, Esophageal Cancer, Colorectal Cancer

25-747          Phase I

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)

  • Ovarian Cancer, Head and Neck Cancer, Cervical Cancer, Breast Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Sarcoma, Pancreatic Cancer, Ovarian Cancer, Liver Cancer, Kidney Cancer, Head and Neck Cancer, Breast Cancer, Thyroid Cancer, Lung Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Ovarian Cancer, Gastric (Stomach) Cancer, Sarcoma

24-169          Phase I

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

  • Ovarian Cancer

25-881          Phase I

A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, As Monotherapy in Participants with Platinum-Resistant Ovarian Cancer

  • Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Breast Cancer

25-490          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors

  • Head and Neck Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Cervical Cancer, Prostate Cancer, Breast Cancer, Bladder Cancer, Colorectal Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Pancreatic Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer

25-783          Phase I

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

  • Lung Cancer, Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck Cancer

25-622          Phase II

A Phase 1/2 Trial of TER-2013 in Participants with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Breast Cancer, Prostate Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Colorectal Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

Showing 1 - 10 of 29 results